Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

View Publication
Abstract:
No abstract specified

SEEK ID: https://seek.lisym.org/publications/381

DOI: 10.1080/13543784.2023.2230115

Projects: DEEP-HCC network, Forschungsnetzwerk LiSyM-Krebs

Publication type: Journal

Journal: Expert Opinion on Investigational Drugs

Citation: Expert Opinion on Investigational Drugs 32(6):451-461

Date Published: 3rd Jun 2023

Registered Mode: by DOI

Authors: Tobias Puengel, Frank Tacke

help Submitter
Citation
Puengel, T., & Tacke, F. (2023). Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH). In Expert Opinion on Investigational Drugs (Vol. 32, Issue 6, pp. 451–461). Informa UK Limited. https://doi.org/10.1080/13543784.2023.2230115
Activity

Views: 384

Created: 10th Aug 2023 at 09:49

Last updated: 8th Mar 2024 at 07:44

help Tags

This item has not yet been tagged.

help Attributions

None

Powered by
 (v.1.14.2)
About FAIRDOM | About LiSyM | Funding and Programmes | Credits | Terms & Conditions | Imprint
Copyright © 2008 - 2023 The University of Manchester and HITS gGmbH